Rocket Pharmaceuticals, Inc. (RCKT): Total Assets
$330.45M
As of 2025-12-31
$423.10M
As of 2026-06-30
-15.7%
3-year compound annual growth
-11.0%
5-year compound annual growth
+11.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $330.45M | -37.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $527.70M | -6.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $566.34M | +2.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $551.81M | +11.0% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $497.02M | -15.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $590.82M | +58.8% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $372.12M | +48.1% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $251.31M | n/m | 2020-03-06, Balance as of period end |
| 2017-12-31 | $20.15M | -84.5% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $129.65M | +14.4% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $113.32M | n/m | 2017-03-16, Balance as of period end |
| 2014-12-31 | $5.52M | n/a | 2016-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $330.45M | -37.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare RCKT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗